Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
6.52
-0.15 (-2.25%)
At close: Jul 24, 2025, 4:00 PM
6.63
+0.11 (1.69%)
After-hours: Jul 24, 2025, 4:29 PM EDT

Company Description

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.

Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases.

The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.

Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Avalo Therapeutics, Inc.
Avalo Therapeutics logo
CountryUnited States
Founded2011
IPO DateOct 15, 2015
IndustryBiotechnology
SectorHealthcare
Employees23
CEOGarry Neil

Contact Details

Address:
540 Gaither Road, Suite 400
Rockville, Maryland 20850
United States
Phone410 522 8707
Websiteavalotx.com

Stock Details

Ticker SymbolAVTX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001534120
CUSIP Number05338F108
ISIN NumberUS05338F3064
Employer ID45-0705648
SIC Code2834

Key Executives

NamePosition
Dr. Garry A. Neil M.D.President, Chief Executive Officer and Director
Christopher Ryan Sullivan CPAChief Financial Officer and Head of Investor relations
Dr. Mittie Doyle FACR, M.D.Chief Medical Officer
Dr. Solomon H. Snyder M.D.Founder and Chairman of Scientific Advisory Board
Dr. Barbara S. Slusher Ph.D.Founder and Member of Scientific Advisory Board
Paul C. Varki J.D., M.P.HChief Legal Officer
Dr. Lisa Hegg Ph.D.Senior Vice President of Program Management, Business Development and Corporate Infrastructure
Colleen MatkowskiSenior Vice President of Global Regulatory Affairs and Quality Assurance
Dr. Dino C. Miano Ph.D.Senior Vice President of CMC and Technical Operations
Jennifer RileyChief Strategy Officer

Latest SEC Filings

DateTypeTitle
Jun 20, 20258-KCurrent Report
Jun 18, 20258-KCurrent Report
Jun 17, 20258-KCurrent Report
Jun 5, 20258-KCurrent Report
Jun 5, 2025424B5Filing
Jun 4, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13GFiling
May 12, 2025S-8Securities to be offered to employees in employee benefit plans